Literature DB >> 24001600

Evaluating the effects of CELF1 deficiency in a mouse model of RNA toxicity.

Yun Kyoung Kim1, Mahua Mandal, Ramesh S Yadava, Luc Paillard, Mani S Mahadevan.   

Abstract

Myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy, is caused by an expanded (CTG)n repeat in the 3' untranslated region of the DM protein kinase (DMPK) gene. The toxic RNA transcripts produced from the mutant allele alter the function of RNA-binding proteins leading to the functional depletion of muscleblind-like (MBNL) proteins and an increase in steady state levels of CUG-BP1 (CUGBP-ETR-3 like factor 1, CELF1). The role of increased CELF1 in DM1 pathogenesis is well studied using genetically engineered mouse models. Also, as a potential therapeutic strategy, the benefits of increasing MBNL1 expression have recently been reported. However, the effect of reduction of CELF1 is not yet clear. In this study, we generated CELF1 knockout mice, which also carry an inducible toxic RNA transgene to test the effects of CELF1 reduction in RNA toxicity. We found that the absence of CELF1 did not correct splicing defects. It did however mitigate the increase in translational targets of CELF1 (MEF2A and C/EBPβ). Notably, we found that loss of CELF1 prevented deterioration of muscle function by the toxic RNA, and resulted in better muscle histopathology. These data suggest that while reduction of CELF1 may be of limited benefit with respect to DM1-associated spliceopathy, it may be beneficial to the muscular dystrophy associated with RNA toxicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24001600      PMCID: PMC3924053          DOI: 10.1093/hmg/ddt419

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  42 in total

1.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts.

Authors:  B M Davis; M E McCurrach; K L Taneja; R H Singer; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing.

Authors:  A N Ladd; N Charlet; T A Cooper
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Age-specific CUGBP1-eIF2 complex increases translation of CCAAT/enhancer-binding protein beta in old liver.

Authors:  Lubov T Timchenko; Elizabeth Salisbury; Guo-Li Wang; Heather Nguyen; Jeffrey H Albrecht; John W B Hershey; Nikolai A Timchenko
Journal:  J Biol Chem       Date:  2006-08-24       Impact factor: 5.157

4.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

5.  CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.

Authors:  Amanda J Ward; Mendell Rimer; James M Killian; James J Dowling; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2010-07-05       Impact factor: 6.150

6.  Global regulation of alternative splicing during myogenic differentiation.

Authors:  Christopher S Bland; Eric T Wang; Anthony Vu; Marjorie P David; John C Castle; Jason M Johnson; Christopher B Burge; Thomas A Cooper
Journal:  Nucleic Acids Res       Date:  2010-07-15       Impact factor: 16.971

7.  Satellite cell dysfunction contributes to the progressive muscle atrophy in myotonic dystrophy type 1.

Authors:  L-E Thornell; M Lindstöm; V Renault; A Klein; V Mouly; T Ansved; G Butler-Browne; D Furling
Journal:  Neuropathol Appl Neurobiol       Date:  2009-01-21       Impact factor: 8.090

8.  Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.

Authors:  Nicolas Charlet-B; Rajesh S Savkur; Gopal Singh; Anne V Philips; Elizabeth A Grice; Thomas A Cooper
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

9.  Repression of nuclear CELF activity can rescue CELF-regulated alternative splicing defects in skeletal muscle models of myotonic dystrophy.

Authors:  Dara S Berger; Andrea N Ladd
Journal:  PLoS Curr       Date:  2012-02-24

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  22 in total

1.  Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.

Authors:  Christina Wei; Lauren Stock; Leila Valanejad; Zachary A Zalewski; Rebekah Karns; Jack Puymirat; David Nelson; David Witte; Jim Woodgett; Nikolai A Timchenko; Lubov Timchenko
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

2.  Hypogonadism Associated with Cyp19a1 (Aromatase) Posttranscriptional Upregulation in Celf1 Knockout Mice.

Authors:  Gaella Boulanger; Marie Cibois; Justine Viet; Alexis Fostier; Stéphane Deschamps; Sylvain Pastezeur; Catherine Massart; Bernhard Gschloessl; Carole Gautier-Courteille; Luc Paillard
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

3.  MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity.

Authors:  Ramesh S Yadava; Yun K Kim; Mahua Mandal; Karunasai Mahadevan; Jordan T Gladman; Qing Yu; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

4.  TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.

Authors:  Ramesh S Yadava; Erin P Foff; Qing Yu; Jordan T Gladman; Yun K Kim; Kirti S Bhatt; Charles A Thornton; Timothy S Zheng; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2014-12-11       Impact factor: 6.150

5.  Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

Authors:  Darren R Bisset; Ewa A Stepniak-Konieczna; Maja Zavaljevski; Jessica Wei; Gregory T Carter; Michael D Weiss; Joel R Chamberlain
Journal:  Hum Mol Genet       Date:  2015-06-16       Impact factor: 6.150

6.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

7.  NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity.

Authors:  Jordan T Gladman; Ramesh S Yadava; Mahua Mandal; Qing Yu; Yun K Kim; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2014-08-28       Impact factor: 6.150

8.  Identification of variants in MBNL1 in patients with a myotonic dystrophy-like phenotype.

Authors:  Mirjam Larsen; Wolfram Kress; Benedikt Schoser; Ute Hehr; Clemens R Müller; Simone Rost
Journal:  Eur J Hum Genet       Date:  2016-05-25       Impact factor: 4.246

9.  Increased nuclear but not cytoplasmic activities of CELF1 protein leads to muscle wasting.

Authors:  Diana C Cox; Xiangnan Guan; Zheng Xia; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2020-06-27       Impact factor: 6.150

10.  miR-322/miR-503 clusters regulate defective myoblast differentiation in myotonic dystrophy RNA-toxic by targeting Celf1.

Authors:  Wei Dong; Qian Liu; Zhi-Chao Wang; Xing-Xiang Du; Lei-Lei Liu; Nan Wang; Jun-Fei Weng; Xiao-Ping Peng
Journal:  Toxicol Res (Camb)       Date:  2021-01-05       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.